Baltimore, MD, September 2, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects
August 14, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee,
CAPITAL After the close of our Seed Prime II round in January, we received significant interest from follow-on investors, so we extended the round through
Dear Colleagues, Nanochon’s 10-year anniversary represents a time for us to reflect on the immense progress we’ve made over the last decade and thank those
CAPITAL Following the formal close of our Seed Prime II round at $4.1M (pre-money valuation: $24M) announced in January, additional funds bring our total capital
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes 4, Brad B Nelson 1,
Capital Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This round was led by Ecphora
This article was originally published on UVA Today This Alum’s Tech May Revolutionize Knee Joint Replacements Benjamin Holmes can pinpoint the exact moment he fell
WASHINGTON, January 12, 2026 — Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects in the knee, has secured
Emilia Aram , David C. Flanigan, MD, Nathan J. Castro, PhD, Doug Snell, Luke Aram Purpose: Osteochondral defects can present a significant source of pain
